Oculis Holding (CR5) Price & Analysis

2 Followers

CR5 Stock Chart & Stats

€22.00

€8.00(72.73%)

At close: Jan 08 4:00 PM EST

€22.00

€8.00(72.73%)

Day’s Range― - ―

52-Week Range€8.82 - €29.30

Previous CloseN/A

Volume0.00

Average Volume (3M)54.00

Market Cap

€630.05M

Enterprise Value€453.91M

Total Cash (Recent Filing)€221.37M

Total Debt (Recent Filing)€2.24M

Price to Earnings (P/E)―

Beta0.35

Next Earnings

Aug 06, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.73

Shares Outstanding57,169,476

10 Day Avg. Volume20

30 Day Avg. Volume54

Financial Highlights & Ratios

PEG Ratio0.60

Price to Book (P/B)4.22

Price to Sales (P/S)0.00

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€33.47

Price Target Upside52.15% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.53

Revenue Forecast (FY)€677.94K

Bulls Say, Bears Say

Bulls Say

Strong Liquidity / Multi-year RunwayReported cash and short-term financial assets and management’s projection of runway into H2 2029 provide durable funding visibility. This multi-year liquidity supports ongoing Phase 3/registrational programs, reducing near-term refinancing pressure and allowing focus on clinical milestones rather than survival financing.

Low Leverage / Strong Balance SheetExtremely low financial leverage and a sizable equity base give the company structural flexibility to fund expensive clinical development via capital markets or partnerships without heavy interest burden. Low debt lowers bankruptcy risk and preserves options for strategic transactions or licensing over the medium term.

Regulatory Designations & Registrational-stage PipelineBreakthrough and PRIME designations plus SPA and registrational-stage status materially de-risk timelines and evidentiary requirements versus earlier-stage assets. These regulatory recognitions can accelerate approval paths, strengthen competitive moats in neuro-ophthalmology, and improve partner/licensing attractiveness long-term.

Bears Say

Sustained Cash BurnPersistent negative operating and free cash flows demonstrate structural cash consumption driven by R&D and G&A. Even with current liquidity, continued burn implies recurring financing needs or dilution unless spending is curtailed or revenue materializes, pressuring long-term capital efficiency and shareholder value.

Minimal Commercial RevenueVery limited revenue against large, recurring losses shows the company remains pre-commercial and lacks operating leverage. Without meaningful product sales, profitability depends entirely on successful trial outcomes or partner deals, increasing structural execution and funding risk over the medium term.

Pipeline Outcome DependencyValue creation is concentrated in a few registrational-stage programs and imminent readouts. This concentration creates binary outcome risk: negative trial results or regulatory setbacks would materially impair commercial prospects and capital plans, making the firm's mid-term viability highly contingent on clinical success.

Oculis Holding News

Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch

Oculis Holding Ag ($OCS) announced an update on their ongoing clinical study. The study “A Randomized, Double-masked, Placebo-controlled...

16d ago

OCS

Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway

The latest announcement is out from Oculis Holding ( ($OCS) ). On June 25, 2026, Oculis Holding AG...

22d ago

OCS

Oculis price target lowered to $23 from $42 at JPMorgan

JPMorgan lowered the firm’s price target on Oculis (OCS) to $23 from $42 and keeps an Overweight rating...

1M ago

OCS

Oculis price target lowered to $38 from $49 at Baird

Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating...

2M ago

OCS

Oculis price target lowered to $38 from $49 at Baird

Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating...

2M ago

OCS

Video: Nvidia rallies after taking wraps off new PC processor

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

2M ago

AMD

OCS

Oculis price target lowered to $35 from $44 at BofA

BofA lowered the firm’s price target on Oculis (OCS) to $35 from $44 and keeps a Buy rating...

2M ago

OCS

Oculis price target lowered to $38 from $46 at Needham

Needham lowered the firm’s price target on Oculis (OCS) to $38 from $46 and keeps a Buy rating...

2M ago

OCS

Oculis price target lowered to $45 from $75 at Guggenheim

Guggenheim lowered the firm’s price target on Oculis (OCS) to $45 from $75 and keeps a Buy rating...

2M ago

OCS

Oculis price target lowered to $26 from $47 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Oculis (OCS) to $26 from $47 and keeps a Buy...

2M ago

OCS

Oculis price target lowered to $40 from $50 at Stifel

Stifel lowered the firm’s price target on Oculis (OCS) to $40 from $50 and keeps a Buy rating...

2M ago

OCS

Oculis Maintained at Buy as Analyst Lowers Price Target to $45, Refocuses on Optic Neuritis Opportunity

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Oculis Holding, with...

2M ago

OCS

Analyst Maintains Buy on Oculis, Sees Upside Driven by Optic Neuropathy and Dry Eye Pipelines Despite OCS-01 Phase 3 Setback

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on OCS stock, giving a Buy rating on...

2M ago

OCS

Oculis Holding AG trading resumes

16:21 EDT Oculis (OCS) Holding AG trading resumes Published first on TheFly – the ultimate source for real-time,...

2M ago

OCS

CR5 FAQ

What was Oculis Holding Ag’s price range in the past 12 months?

Oculis Holding Ag lowest stock price was €8.82 and its highest was €29.30 in the past 12 months.

What is Oculis Holding Ag’s market cap?

Oculis Holding Ag’s market cap is €630.05M.

When is Oculis Holding Ag’s upcoming earnings report date?

Oculis Holding Ag’s upcoming earnings report date is Aug 06, 2026 which is in 19 days.

How were Oculis Holding Ag’s earnings last quarter?

Oculis Holding Ag released its earnings results on May 11, 2026. The company reported -€0.531 earnings per share for the quarter, missing the consensus estimate of -€0.434 by -€0.098.

Is Oculis Holding Ag overvalued?

According to Wall Street analysts Oculis Holding Ag’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oculis Holding Ag pay dividends?

Oculis Holding Ag does not currently pay dividends.

What is Oculis Holding Ag’s EPS estimate?

Oculis Holding Ag’s EPS estimate is -0.43.

How many shares outstanding does Oculis Holding Ag have?

Oculis Holding Ag has 57,169,476 shares outstanding.

What happened to Oculis Holding Ag’s price movement after its last earnings report?

Oculis Holding Ag reported an EPS of -€0.531 in its last earnings report, missing expectations of -€0.434. Following the earnings report the stock price went down -4.24%.

Which hedge fund is a major shareholder of Oculis Holding Ag?

Currently, no hedge funds are holding shares in DE:CR5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oculis Holding Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.09%

Trailing 12-Months

Asset Growth

31.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oculis Holding Ag

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Oculis Holding (CR5) Earnings & Revenues

Historic Earnings Reports

CR5 Stock 12 Month Forecast

Average Price Target

€33.47

▲(52.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","47":"€47","19.25":"€19.25","28.5":"€28.5","37.75":"€37.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46.32041159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€46.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.473052149,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€33.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.10131069,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,19.25,28.5,37.75,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,14.224647045384616,16.89929409076923,19.573941136153845,22.24858818153846,24.923235226923076,27.59788227230769,30.272529317692307,32.94717636307692,35.62182340846154,38.296470453846155,40.971117499230765,43.645764544615375,{"y":46.32041159,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,13.236388626846153,14.922777253692308,16.609165880538463,18.295554507384615,19.981943134230768,21.66833176107692,23.354720387923077,25.04110901476923,26.727497641615383,28.413886268461535,30.10027489530769,31.786663522153844,{"y":33.473052149,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,12.20779313,12.86558626,13.52337939,14.18117252,14.83896565,15.49675878,16.15455191,16.81234504,17.47013817,18.1279313,18.78572443,19.443517559999997,{"y":20.10131069,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.55,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >